Naseer joined CellCentric in January 2025.
Naseer brings extensive late-stage haem-oncology product development and commercialization experience to CellCentric. Most recently he has had executive roles at Roche/Genentech providing strategic advice and new opportunity evaluation across hematology franchises. He has been involved in the development and launch of multiple oncology drugs and line extensions, including Darzalex, Polivy, Venclexta, Lunsumio and Columvi.
Naseer qualified in medicine at Glasgow University in 2004 and went on to obtain his doctoral degree from Oxford University in 2012. Trained as a physician-scientist, he spent the first part of his career in clinical academia, focusing on translational oncology at Oxford, McGill and Southampton before transitioning to the pharmaceutical industry. He spent over a decade in late-stage product development in haem-oncology (Johnson & Johnson, AbbVie, Roche) across several roles, including Clinical Development, Medical Affairs and Strategy.